Huang Chuan, Sun Yao-Guang, Wu Qing-Jun, Ma Chao, Jiao Peng, Wang Yong-Zhong, Huang Wen, Tian Wen-Xin, Yu Han-Bo, Li Dong-Hang, Tong Hong-Feng
Department of Thoracic Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Transl Cancer Res. 2022 Oct;11(10):3535-3547. doi: 10.21037/tcr-22-1150.
Thymic neuroendocrine neoplasms (Th-NENs) are extremely rare. Th-NENs are divided into four pathological subtypes: typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCC). The latter three subtypes are highly aggressive with poor prognosis. There are limited reports on the optimal surgical strategies for Th-NENs. This study aims to report a case series of Th-NENs after surgical treatment and review the literatures.
We report a case series of five patients diagnosed with Th-NENs and summarize their clinical characteristics. Literatures related to surgical treatment of Th-NENs were reviewed.
There were three males and two females, and mean age was 53.6 years. No myasthenia gravis or neuroendocrine symptoms were found. Three patients were diagnosed with AC and the other two were diagnosed with LCNEC. Two patients were stage II-b, one patient was stage III-a, and two patients were stage IV-b. One patient received preoperative chemotherapy, one patient received preoperative chemoradiotherapy, and three patients underwent surgery directly. Two patients underwent extended thymectomy via video-assisted thoracoscopic surgery (VATS), two patients underwent extended thymectomy via median sternotomy, and one patient underwent resection of anterior mediastinal tumor, sternal metastases, superior vena cava and partial right atrium via median sternotomy and cardiopulmonary bypass. R0 resection was achieved in 80% (4/5) of patients. There was no postoperative 90-day complication and death. One patient had no recurrence. One patient had lymph node metastases and was still alive after somatostatin analogue therapy. One patient had no recurrence of Th-NENs but died of other tumors. Two patients had distant metastases. Median overall survival (mOS) was 49 (range, 4-134) months. A total of 22 original studies related to surgical treatment of Th-NENs were retrieved.
Th-NENs is a very rare and extremely aggressive malignancy. Early diagnosis and surgical resection are the most important methods to improve prognosis. Radical resection and lymph node dissection are recommended for accurate staging and better prognosis. Currently, there are few clinical data on Th-NENs and several important surgical issues remain unresolved. In the future, multi-center, large-sample database and clinical studies are urgently needed to explore better treatment modality.
胸腺神经内分泌肿瘤(Th-NENs)极为罕见。Th-NENs分为四种病理亚型:典型类癌(TC)、非典型类癌(AC)、大细胞神经内分泌癌(LCNEC)和小细胞癌(SCC)。后三种亚型侵袭性强,预后差。关于Th-NENs的最佳手术策略的报道有限。本研究旨在报告一组Th-NENs手术治疗后的病例系列并回顾相关文献。
我们报告一组5例诊断为Th-NENs的患者病例系列,并总结其临床特征。回顾了与Th-NENs手术治疗相关的文献。
男性3例,女性2例,平均年龄53.6岁。未发现重症肌无力或神经内分泌症状。3例患者诊断为AC,另外2例诊断为LCNEC。2例患者为II - b期,1例患者为III - a期,2例患者为IV - b期。1例患者接受术前化疗,1例患者接受术前放化疗,3例患者直接接受手术。2例患者通过电视辅助胸腔镜手术(VATS)行扩大胸腺切除术,2例患者通过正中胸骨切开术行扩大胸腺切除术,1例患者通过正中胸骨切开术及体外循环切除前纵隔肿瘤、胸骨转移灶、上腔静脉及部分右心房。80%(4/5)的患者实现了R0切除。术后90天无并发症及死亡。1例患者无复发。1例患者有淋巴结转移,接受生长抑素类似物治疗后仍存活。1例患者Th-NENs无复发,但死于其他肿瘤。2例患者有远处转移。中位总生存期(mOS)为49(范围4 - 134)个月。共检索到22项与Th-NENs手术治疗相关的原始研究。
Th-NENs是一种非常罕见且侵袭性极强的恶性肿瘤。早期诊断和手术切除是改善预后的最重要方法。建议行根治性切除及淋巴结清扫以准确分期并获得更好的预后。目前,关于Th-NENs的临床数据很少,一些重要的手术问题仍未解决。未来,迫切需要多中心、大样本数据库及临床研究来探索更好的治疗方式。